Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-Bipolar-1: Brenipatide Adjunctive Therapy in Bipolar Disorder
jRCT2021250043Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Modality
- Peptides
01
Overview
Phase 2, randomised, double-blind trial of brenipatide in bipolar disorder (BD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to relapse. Started Feb 2026; status: recruiting.
02
Drugs
brenipatide
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on jRCT2021250043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250043.